VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.
VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.
Company Details
- Employees
- 2
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.vaxequity.com/
Vaxequity Ltd Questions
Vaxequity Ltd's website is https://www.vaxequity.com/
Vaxequity Ltd's LinkedIn profile is https://www.linkedin.com/company/vaxequity-ltd
Vaxequity Ltd has
2 employees.
View email and phone details for 2
employees at Vaxequity Ltd.
Vaxequity Ltd's industry is
Biotechnology Research
Vaxequity Ltd's top competitors are
Ethris,
Replicate Bioscience, Inc.,
Genetic Leap,
Eurofins Cdmo,
Nchroma Bio,
Ono Pharmaceutical Co., Ltd.,
Maxion Therapeutics,
Curevac,
Atalanta Therapeutics,
Etherna.
Vaxequity Ltd's categories are Biotechnology Research
